To determine whether decreased renal responsiveness to atrial natriuretic peptide (ANP) in diabetes is mediated by alterations in the renal ANP receptor, ANP receptor density and affinity were measured 17-20 d after streptozotocin injection and compared with values in vehicle-treated controls and streptozotocin-treated rats made euglycemic with insulin. Plasma ANP concentration was significantly greater in hyperglycemic diabetic rats than in control or euglycemic diabetic rats. Both in glomeruli and inner medulla, ANP receptor dissociation constant did not differ among the three study groups, whereas the maximum binding capacity was decreased significantly in hyperglycemic diabetics in comparison with controls and euglycemic diabetics. Glomerular clearance receptors were also decreased significantly in hyperglycemic diabetic rats in comparison with control and euglycemic diabetic rats. To determine whether the decreased number of renal ANP receptors in diabetic rats was associated with a decreased biological response, we measured ANPdependent cyclic GMP (cGMP) accumulation by isolated glomeruli and inner medullary collecting duct cells in vitro. cGMP accumulation was significantly less in hyperglycemic diabetic rats than in controls or euglycemic diabetic rats both in the presence or absence of the phosphodiesterase inhibitor zaprinast. cGMP phosphodiesterase activity in inner medullary collecting duct cells obtained from control and hyperglycemic diabetic rats did not differ. Thus, the decreased number of biologically active ANP receptors in the kidneys of diabetic rats is […] decreased significantly in hyperglycemic diabetics in comparison with controls and euglycemic diabetics. Glomerular clearance receptors were also decreased significantly in hyperglycemic diabetic rats in comparison with control and euglycemic diabetic rats. To determine whether the decreased number of renal ANP receptors in diabetic rats was associated with a decreased biological response, we measured ANP-dependent cyclic GMP (cGMP) accumulation by isolated glomeruli and inner medullary collecting duct cells in vitro. cGMP accumulation was significantly less in hyperglycemic diabetic rats than in controls or euglycemic diabetic rats both in the presence or absence of the phosphodiesterase inhibitor zaprinast. cGMP phosphodiesterase activity in inner medullary collecting duct cells obtained from control and hyperglycemic diabetic rats did not differ. Thus, the decreased number of biologically active ANP receptors in the kidneys of diabetic rats is accompanied by decreased biological responsiveness in vitro and provides a potential explanation for the reduction in renal sensitivity to ANP in this condition. (J. Clin. Invest. 1995. 95:2451-2457
Introduction
Increased exchangeable sodium (1, 2) and extracellular fluid volume (3) occur in diabetic humans and experimental animals, respectively. Whereas the kidney is the principal organ responsible for the chronic regulation of body sodium and fluid composition (4), renal disease per se is an unlikely explanation for these abnormalities since they can occur quite early in the disease, even when glomerular filtration rate is normal and proteinuria is minimal (1, 2) . Enhanced renal tubular reabsorption and/ or impaired responses to natriuretic influences are more likely explanations.
In both rats (5-7) and humans (8) with insulinopenic diabetes, the glomerular and tubular response of the kidney to atrial natriuretic peptide (ANP)' is decreased. The basis for this decreased responsiveness has not been established, but may involve an abnormality of renal ANP receptors. Three distinct natriuretic peptide receptors have been identified (9) : ANPR-A and ANPR-B, also called GC-A and GC-B, are both membrane guanylyl cyclases that synthesize cyclic GMP (cGMP) as an intracellular second messenger (9, 10) . ANPR-C, also known as the ANP clearance receptor, does not signal through activation of guanylyl cyclase, but may serve as a clearance receptor for natriuretic peptides; it may also function through intermediate guanine nucleotide regulatory proteins to inhibit adenylyl cyclase (11). While ANPR-A and ANPR-B have rather strict structural requirements for ligand binding (12) (13) (14) (15) , ANPR-C has less rigorous structural requirements and binds the internally deleted analogues of ANP (c-ANP) (12, (16) (17) (18) , compounds which do not activate the membrane guanylate cyclase.
ANPR-A and ANPR-C receptors and their mRNAs have been demonstrated in the kidney using in situ autoradiographic techniques (19, 20) and in situ hybridization (21) , respectively. This study was designed to investigate the type, number, and affinity of ANP receptors in the kidney of rats with streptozotocin (STZ)-induced diabetes and to assess the biological activity of these receptors by measuring ANP-dependent cGMP accumulation by glomeruli and inner medullary collecting duct cells (IMCD) isolated from these rats.
Methods
Preparation of diabetic rats. Male Sprague-Dawley rats (Bantin and Kingman, Inc., Fremont, CA), ranging in weight from 200 to 250 g, were maintained on standard rat chow and tap water ad libitum with a 12-h light/dark cycle in a quiet environment. In 19 rats, diabetes mellitus was induced by intravenous administration of STZ (Sigma, Chemical Co., St. Louis, MO), 60 mg/kg body wt, dissolved in sodium citrate buffer (0.1 mol/liter, pH 4.5) at a concentration of 20 mg/ml immediately before use. Control rats (n = 11), which were matched for age and weight at the time of STZ administration, received an equal volume of the vehicle. Animals were considered to be diabetic if blood glucose 1. Abbreviations used in this paper: ANP, atrial natriuretic peptide; B., maximum binding capacity; IMCD, inner medullary collecting duct; PDE, phosphodiesterase; STZ, streptozotocin. levels were 350 mg/dl or greater 72 h after the injection. Diabetic rats were further divided into two subgroups: rats to which human recombinant insulin (Humulin N; Eli Lilly & Co., Indianapolis, IN) was administered once daily in a fixed dose (2 U/d, n = 11) to prevent ketosis, and rats to which insulin was administered in doses that were adjusted to achieve euglycemia (6-10 U/d, n = 8). Blood glucose levels were measured on a drop of blood obtained by tail vein nicking (Accucheck bG; Bio-Dynamics, Boehringer-Mannheim, Indianapolis, IN). To determine the 24-h urine volume and the rate of excretion of sodium and cGMP, rats were placed in metabolic cages on the day before killing. Rats were killed by decapitation 17-20 d after the administration of STZ, and trunk blood was collected for determination of plasma glucose and ANP levels. The kidneys were quickly removed, decapsulated, snapfrozen in liquid nitrogen, and stored at -800C. Plasma ANP was measured by radioimmunoassay (Peninsula Laboratories, Inc., Belmont, CA), after extraction with 0.1% trifluoroacetic acid and 75% methanol.
Receptor binding studies. The density of ANP receptors was assessed by a modification of an in situ receptor binding assay (19) as reported previously (20) . Briefly, tissue sections (10 jLm) were cut on a cryostat at -15'C, thaw-mounted on poly-L-lysine-coated slides, dried in vacuo for 18 h at -4 to +40C over silica gel, and stored in sealed Bakelite boxes at -80mC. Immediately before assay, the slides were brought to room temperature. Sections were preincubated for 10 min at room temperature in 100 ul of a buffer (buffer A) containing 30 mM sodium phosphate (pH 7.2), 120 mM sodium chloride, 0.3% bacitracin, and 0.5% receptor grade bovine serum albumin. After preincubation, the buffer was replaced with 100 sll of fresh buffer A containing increasing concentrations (from 25 to (5-10 ml) . Glomeruli were isolated as described previously (23) . In brief, for each preparation the renal cortices were dissected and minced to a pastelike consistency. The homogenate was passed successively through a 106-pAm sieve that excluded the tubules and blood vessels and a 75-/Am sieve that retained the glomeruli and allowed cells and small debris to pass through. Glomeruli were suspended in ice-cold 20 mM Tris-HCl buffer, pH 7.4, containing 135 mM sodium chloride, 10 mM potassium chloride, 10 mM sodium acetate, and 5 mM glucose (buffer B) and centrifuged at 120 g for 2 min. The supernatant was discarded, and the pellet was resuspended in the same buffer and recentrifuged. by radioimmunoassay. cGMP production was linear as a function of incubation time (1-10 min) and protein concentration (10-100 Ag).
Protein concentration was determined by the Coomassie protein assay.
Determination of PDE activity in IMCD cells. cGMP PDE activity was assayed according to the method of Torres et al. (27) . Cytosolic fractions of IMCD cell homogenates, collected as described (10) (11) (12) (13) (14) (15) Values are means±SEM. Significant difference versus control rats is indicated by * P < 0.01, and * P < 0.05.
Comparisons were done by ANOVA (Statview; BrainPower Inc., Calabasas, CA). A P value < 5% was considered to be statistically significant.
Results
Blood glucose, body weight, and plasma ANP. Hyperglycemia occurred within 3 d of administration of STZ and persisted thereafter in the rats that received low-dose insulin therapy (Fig.  1 , Table I ). Hyperglycemia was completely ameliorated in the rats that received the higher doses of insulin (Fig. 1 , Table I ). Rats treated with the higher doses of insulin gained weight rapidly, reaching values not significantly different from control at the end of the experimental period (Fig. 1, Table I ), whereas the rate of growth was significantly slower in the rats with persistent hyperglycemia. The kidney weight at the end of the experiment was comparable in the three groups, although the kidney weight/body weight ratio was significantly greater (P < 0.01) in the hyperglycemic diabetic than in control and euglycemic diabetic rats (Table I) . Plasma levels of ANP were significantly greater in hyperglycemic diabetic rats than in control rats (Table I ). The administration of insulin to diabetic rats in doses sufficient to maintain their blood glucose concentration within the normal range resulted in a normalization of plasma levels of ANP.
ANP receptor binding. The distribution of ["5I]-rat ANP binding in the kidney of control rats is shown in Fig. 2 A. Binding of radioligand was found in both cortical and medullary regions of rat kidney. In the cortex, the radioligand binding was localized primarily in glomeruli. In the outer medulla, bound radioligand was found in longitudinal bands in the inner stripe, corresponding to medullary vascular bundles (29) . Minimal radioligand binding was found in the interbundle areas, whereas binding to papillae was high. Nonspecific binding was < 10% (Fig. 2 B) . Incubation with c-ANP markedly reduced binding of the radioligand to glomeruli (Fig. 2 C) . A similar distribution of radioligand binding and pattern of inhibition by unlabeled ANP and c-ANP were found in the kidney of diabetic rats (Fig.  2 D) . Increasing concentrations of radioligand resulted in an increase in both total and nonspecific binding. Receptor saturation was approached at 1.2 nmollliter in both control and hyperglycemic diabetic rats (Fig. 3) . Scatchard analysis of these data sug- Radlollgand Concentraton (pM) Figure 3 . gested the presence of a single receptor site in each of the three experimental groups (Fig. 4) . ANP receptor affinity, expressed as the apparent Kd, did not differ among the three study groups, whereas the Bm, for ANP was significantly decreased in hyperglycemic diabetic rats as compared with controls and normoglycemic diabetic rats. Regional analysis of ANP binding was performed by computerized microdensitometry and showed that ANPR-A receptor density was decreased both in glomeruli and inner medulla in the hyperglycemic diabetic rats. Equilibrium binding data obtained in glomeruli in the presence of c-ANP showed that the number of ANPR-C receptors was significantly lower in the kidney of hyperglycemic diabetic rats in comparison with controls and euglycemic diabetics (Table II) . cGMP accumulation by glomeruli and IMCD cells and guanylate cyclase activity. ANP induced a dose-dependent increase in glomerular cGMP generation in the three groups (Fig. 5) . Both in glomeruli and IMCD cells, cGMP accumulation was lower in hyperglycemic diabetic rats than in controls at the higher concentrations used. Similar differences between hyperglycemic diabetic and control rats were found when glomeruli were incubated in the presence of zaprinast (Fig. 6) , indicating that these differences could not be ascribed to an alteration in the activity of cGMP PDE. Guanylate cyclase activity was comparable in membranes obtained from IMCD cells in control (5,983±548 fmol GMP mg protein-' * min-) and hyperglycemic diabetic (5,835±814 fmol GMP-mg protein-' * min-) rats, indicating no effect of diabetes on basal activity of this enzyme.
PDE enzymatic activity in IMCD cells. Measurement of PDE enzymatic activity in IMCD cytosol showed comparable values in control (180±28 fmol-mg protein-' -min-') and hyperglycemic diabetic rats (156±23 fmol-mg protein-1-min-'; NS).
Discussion
This study demonstrates that the number of ANP receptors is decreased in the kidney of rats with STZ-induced diabetes melli- 2454 Sechi et al.
Xw tus. This abnormality is associated with a decreased production of cGMP by glomeruli and IMCD cells which is not corrected by inhibition of PDE activity.
When studied 2 wk after administration of STZ, we found that plasma ANP levels in hyperglycemic diabetic rats were significantly increased in comparison with controls and that insulin therapy sufficient to achieve strict glycemic control normalized plasma ANP levels. In previous studies, plasma ANP levels in diabetic rats were increased as early as 1 wk after STZ injection (30) and persisted at elevated levels for at least 6 wk (7, 31) . Plasma ANP levels are also increased in patients with insulin-dependent diabetes mellitus and diabetic nephropathy Values are means±SEM. Significant differences versus control rats are indicated by * P < 0.05, and * P < 0.01. In both glomeruli and IMCD cells, cGMP production was lower in low-dose insulin-treated diabetic rats than in controls at the higher concentrations used. Data are mean±SEM of eight control, four low-dose, and five high-dose insulintreated rats for glomeruli and six control, five low-dose, and four highdose insulin-treated rats for IMCD cells. (8, (32) (33) (34) (35) . This increase in ANP levels could be a consequence of the plasma volume expansion present in both STZ-diabetic rats (7, 31, 36, 37) and patients with diabetes mellitus (2, (38) (39) (40) (41) . Despite increased plasma levels of ANP, the response to maneuvers known to stimulate the release of the peptide, such as saline infusion, is impaired (5, 31) . This has been interpreted as a consequence of partial exhaustion of the storage pool of the hormone as also demonstrated by morphologic studies in which the abundance of secretory granules is decreased in atrial cardiomyocytes obtained from diabetic rats (31, 42) . Blunted glomerular and tubular responses to volume expansion (5, 6) and exogenous ANP infusion (7) have been reported in rats with STZ-induced diabetes. Similarly, a decreased natriuretic response to endogenously secreted ANP has been shown in type 1 diabetic subjects after head-out water immersion (8) .
In the present study, we found that the number of both biological and clearance ANP receptors is significantly decreased in the kidneys of STZ-diabetic rats, providing an explanation for the decreased renal response to the hormone. Similarly, Benigni et Circulating levels of peptide hormones may directly regulate target tissue receptor number, and plasma concentrations may negatively correlate with the density of specific receptors (46) . This also applies to circulating ANP, the levels of which determine receptor density in the kidney (47) (48) (49) (log M) through changes in the activity of protein kinase C. Further studies will be required to distinguish among these various posmerular cGMP accumulation in control and low-dose insusibilities. lin-treated rats, in the presence of zaprinast. ANP induced a dosedependent increase in cGMP in both groups. cGMP generation was lower in low-dose insulin-treated diabetic rats at the highest concentration used. Glomerular cGMP generation in high-dose insulin-treated diabetic rats was identical to that shown for control rats. Data are mean±SEM of eight control, four low-dose, and five high-dose insulintreated rats.
In summary, our results demonstrate a reduced binding of ANP in both glomeruli and IMCD cells of diabetic rat kidneys. The diminished binding is associated with diminished biological activity in vitro in these target sites of renal ANP action. This abnormality may consequently be the mechanism underlying renal resistance to ANP in diabetic animals and patients. Acknowledgments al. (7) reported a reduction in the number of cortical ANP receptors in rats with STZ-induced diabetes 6 wk after injection. In that study, however, no distinction was made between clearance and biological receptors. Consistent with our findings, no change in receptor affinity was found by those investigators. A reduction in the number of clearance receptors, together with the persistent stimulation of ANP release from atria due to an increase in extracellular fluid volume, could explain the increase in plasma ANP levels found in STZ diabetes.
Most renal actions of ANP are thought to be mediated by cGMP (43, 44) . Measurement of cGMP in glomeruli incubated in the presence of increasing concentrations of ANP indicated that the glomerular response to the hormone is significantly reduced in STZ-diabetic rats, providing indirect evidence of decreased renal sensitivity to ANP. A decreased response to ANP could be explained by an increased activity of cGMP PDE as described in other proteinuric conditions (45) 
